Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
NORCROSS, Ga., March 07, 2016 -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces today Peter G. Traber, M.D., the Company’s president, chief executive officer and chief medical officer, will present at the 28th Annual ROTH Conference on Monday, March 14th, 2016 at 4:00 p.m. Pacific time. The conference is being held at the Ritz-Carlton, Laguna Niguel in Dana Point, California from March 13-16, 2016.
The ROTH Conference presentation will be webcast, and may be found on the company’s website at www.galectintherapeutics.com. The webcast and presentation will be archived on the company's website for 90 days following the event.
About Galectin Therapeutics
Galectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.
Contacts
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]
LHA
Kim Golodetz
(212) 838-3777
[email protected]
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc.
